Skip to main content
Michigan OPEN

Public Health Policy

OPEN is committed to supporting evidence-based policies to improve opioid prescribing and disposal. Legislation at the state and federal level can help address the many complex issues related to opioid overuse and overdose. Policies implemented in the state of Michigan cover a variety of opioid related topics, including prescribing controlled substances, overdose treatment, medications for opioid use disorder, naloxone, and the non-opioid directive.

Current Legislation

JurisdictionBill NumberSummaryStatusLast Activity
StateSB 0133Overdose Fatality Review Act: allows a county to establish an overdose fatality review team and prescribe its membership, set duties and responsibilities, submit annual report, confidentiality requirementsOrdered enrolled (passed by Senate and House)11/9/23
StateHB 5178Provide for syringe service programsReferred to committee10/18/23
StateHB 5179Modify definition of drug paraphernaliaReferred to committee10/18/23
StateHB 4734
HB 4735
HB 4736
HB 4737
Require school districts to obtain naloxone and distribute to schools; require local govt. to provide access to naloxone; and require local govt. to provide trainingReferred to committee6/14/23

Table last updated: 12/5/23

Current Bills and Passed Legislation Information:  

OPEN's Areas of Expertise

OPEN’s policy mission is to develop and disseminate evidence to policy-relevant audiences in order to increase knowledge and promote best practices surrounding acute care episodes to improve treatment, outcomes and overall health.

Opioids are commonly prescribed after surgery for pain management and many patients receive their first exposure to opioids following surgery. Prescribers have little guidance available on opioids and overprescribing is a widespread problem that contributes to the opioid epidemic currently claiming 130 American lives every day. With up to 92% of patients having leftover opioids after common operations, millions of pills are left vulnerable to diversion into communities.

Key Takeaways: 

  • Becoming a new chronic opioid user is the most common post-surgical complication
  • Prescribing often far exceeds pain management needs
  • Prescription size is the strongest predictor of how much opioid a person will use
  • Evidence-based policies are needed to improve opioid prescribing after surgery


Key Publications:

Opioid prescribing increased 68% from 2010 to 2016 in the field of dentistry. Many people are exposed to opioids for the first time after dental surgery, such as wisdom tooth removal.  Patients who took opioids reported higher pain, and there was no difference found in satisfaction between patients who took opioids and who did not.

Key Takeaways:

  • Dentistry is a common first exposure to opioids
  • 80% of patients who were not using opioids before wisdom tooth extraction filled an opioid prescription at the time of surgery.
  • Opioid prescriptions filled for wisdom tooth removal had 3 times the odds of developing persistent opioid use in the year after surgery
  • Evidence-based policies are needed to improve opioid prescribing after dental procedures


Key publications:

Surgical and dental procedures are among the most frequent indications for opioid prescriptions to adolescents and young adults. Rates of new persistent opioid use among pediatric patients are comparable to those for adults, with 4.8% of patients refilling opioid prescriptions between 3 and 6 months after surgery. 

For more information on OPEN’s current projects:

  • Policy Brief One-Pager (in production)

Key publications:

Among surgical patients who developed new persistent opioid use, surgeons provided the majority of opioid prescriptions during the first three months after surgery. By nine to twelve months after surgery, however, the majority of opioid prescriptions were provided by primary care physicians. Enhanced care coordination between surgeons and primary care physicians can allow earlier identification of patients at risk for new persistent opioid use to prevent misuse and dependence.

For more information on current projects: 

Key publications:

While there is a growing prevalence of naloxone fills among insured U.S. adults receiving opioids, overall prevalence of naloxone prescribing remains extremely low. Key factors associated with opioid overdose risk were also associated with receiving naloxone. However, history of overdose was not associated with filling a naloxone prescription. Substantial further work is needed to increase naloxone access for patients at risk for opioid overdose.

For more information on current projects: 

Key publications:

6.0% of pregnant women filled an opioid prescription during pregnancy, and 4.0% of the women who filled developed new persistent opioid use. Having a non-delivery procedure in pregnancy and having an emergency room visit during pregnancy are factors associated with filling an opioid in pregnancy. Filling a peripartum opioid prescription (1 week prior to or 3 days post-discharge) was significantly associated with new persistent opioid use.

Key publications: 

Michigan Policy

Public Act* No.DescriptionEffective Date
Prescribing Controlled Substances
PA 247 of 2017Requires prescribers to have a bona fide prescriber-patient relationship in order to prescribe a controlled substance.Jan 2019
PA 251 of 2017Limits acute pain opioid prescriptions to 7-day period and supply. Allows pharmacists to partially fill a controlled substance (Schedule 2) prescription.July 2018
PA 248 of 2017Requires prescriber to obtain and review a MAPS report prior to prescribing or dispensing a controlled substance prescription exceeding a 3-day supply.June 2018
PA 246 of 2017Requires prescriber to educate the patient and have an attestation form signed prior to issuing a control substance prescription.June 2018
Overdose Treatment
PA 250 of 2017Requires professionals treating a patient for an opioid-related overdose to provide information on Substance Use Disorder (SUD) treatment services.March 2018
Medication Assisted Treatment
PA 19 of 2022Removes prior authorization on medications used to treat opioid use disorder, including buprenorphine, for patients with Michigan Medicaid.June 2022
DHHS (Federal)Requires prescribers to obtain an X-waiver before prescribing buprenorphine, but
requirements for training and the provision of psychosocial services have been
April 2021
PA 176 of 2022Allows the distribution of naloxone community-based organizations, such as a nonprofit organizations or social service providers, under a standing order and protects from liability.July 2022
PA 39 of 2019Allows agencies to purchase and possess an opioid antagonist and distribute it to a trained employee. Allows the employee to administer it to an individual who they believe is experiencing an opioid-related overdose.Sept 2019
PA 383 of 2016Allows pharmacists to dispense Naloxone without an individual prescription and without identifying a particular patient (aka Naloxone standing order).March 2017
PA 307 of 2016Protects from liability individuals who administer naloxone in good faith to someone whom they believe to be suffering an opioid-related overdose.Jan 2017
Non-Opioid Directive
PA 42, PA 43, PA 44 of 2022Requires insurer to provide non-opioid directive form upon enrollment/renewal;
requires insurer to post form on website; requires hospital to post form on website.
March 2022
PA 41 of 2022Provides exception to non-opioid directive that allows certain prescribers to administer opioids for intraoperative use.March 2022
PA 554 of 2018Allows patients to fill out a state form that directs health professionals and emergency medical services personnel to not administer opioids to them.March 2019

Table last updated: October 2022

*A public act is a bill that has been approved by the Legislature and signed into law. This version is as originally passed and does not include updates from subsequent legislation (see Michigan Compiled Laws).

**Naloxone, also known by its brand name Narcan®, is a medication intended for the reversal of an overdose that occurs after consumption or use of one or more opioids or opioid-related substances.

Current Michigan Opioid Policies

Take a look at the current opioid policies in Michigan.



Michigan Policy Care Impact

How will the Michigan opioid laws impact your care?

Before you receive a prescription, your doctor:

  • Will educate you about the risks of opioid use
  • Will have you sign a form stating you received the education
  • Will only write a maximum 7-day prescription for acute pain
  • Will run and review a MAPS* report of your medication history

*MAPS, Michigan Automated Prescription System, is a tool that tracks past and current prescriptions written for you.

Michigan Opioid Laws

This resource helps patients understand requirements and limitations, mandated by Michigan law, when writing for prescription opioids.


2017 Michigan Opioid Laws & Frequently Asked Questions (FAQs)

  • Created and managed by the Department of Licensing and Regulatory Affairs (LARA) and the Michigan Department of Health and Human Services (MDHHS).

Michigan Opioid Legislation Tracking Tool

  • Includes State of Michigan legislation from 2019 – present and is managed by the Michigan Injury Prevention Center

Opioid Start Talking Form

  • PA 246 of 2017 requires prescribers to provide opioid education using the states or similar Start Talking Form when prescribing an opioid (See Opioid Education).

Michigan Automated Prescription System (MAPS): Information and Tutorials

  • MAPS is Michigan’s prescription drug monitoring system (PDMP), used to track controlled substances. It is a tool used by prescribers and dispensers to assess patient risk and is also used to prevent drug abuse and diversion at the prescriber, pharmacy, and patient levels.

Opioid Prescribing in Michigan: Navigating the MAPS system

  • Video on how to interpret a MAPS report.

Naloxone Standing Order for Pharmacists

  • Michigan pharmacists interested in providing naloxone to Michigan families under the Standing Order can complete this form.


  • Naloxone Standing Order: Law and statewide standing order that allows a trained pharmacist to dispense naloxone to anyone at risk or in a position to help someone at risk without a prescription (
  • Non-Opioid Directive: a form that can be filled out by patients that allows them to notify health professionals that they do not want to be administered opioids ( 
  • Prescription Drug Monitoring Programs (PDMPs): an electronic database that tracks controlled substance prescriptions in a state (CDC). In Michigan, providers are required to review the Michigan Automated Prescription System (MAPS) before prescribing a 3-day supply or more of opioids (

Contact Us